9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x

• https://twitter.com/Yuz6Yusof/status/1801654266823671968/photo/1

SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years. https://t.co/778buNUq1C https://t.co/4ub8VbrLb6

• SLE Preview: abolishing refractory with CAR-T and better B-cell therapies | Rhe…

#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly

• EULAR 2024 Daily Recap: Days 1 & 2
• https://twitter.com/Yuz6Yusof/status/1801555153968882024/photo/1

#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo

• https://twitter.com/Yuz6Yusof/status/1801347418086326323/photo/1

🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry ➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs ➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL @RheumNow #EULAR2024